Shareholders might have noticed that Inogen, Inc. (NASDAQ:INGN) filed its quarterly result this time last week. The early response was not positive, with shares down 6.2% to US$6.05 in the past week. The results look positive overall; while revenues of US$95m were in line with analyst predictions, statutory losses were 8.7% smaller than expected, with Inogen losing US$0.14 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Inogen after the latest results.

Following last week's earnings report, Inogen's three analysts are forecasting 2026 revenues to be US$360.6m, approximately in line with the last 12 months. Losses are supposed to decline, shrinking 15% from last year to US$0.78. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$369.3m and losses of US$0.78 per share in 2026.

The analysts lifted their price target 8.6% to US$12.67per share, with reduced revenue estimates seemingly not expected to have a long-term impact on the intrinsic value of the business. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Inogen analyst has a price target of US$14.00 per share, while the most pessimistic values it at US$12.00. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. One thing stands out from these estimates, which is that Inogen is forecast to grow faster in the future than it has in the past, with revenues expected to display 3.6% annualised growth until the end of 2026. If achieved, this would be a much better result than the 0.7% annual decline over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 7.6% annually for the foreseeable future. Although Inogen's revenues are expected to improve, it seems that the analysts are still bearish on the business, forecasting it to grow slower than the broader industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. On the negative side, they also downgraded their revenue estimates, and forecasts imply they will perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Inogen going out to 2028, and you can see them free on our platform here..

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.